RNatives

Startup

RNatives leverages the power of nuclear microRNA biology (”nuclear RNAi”) to precisely target gene expression in specific cells. Utilizing our understanding of the natural biological pathways, where small RNAs can alter epigenetics of gene regulatory elements and thus induce long-term effects in gene expression, we can develope efficient, novel RNA therapeutics. The concept and our proprietary RNA platform is meticulously developed by our Founder and CSO, Mikko Turunen, and his dedicated research group. Our lead asset, poised for clinical trials, targets Vascular Endothelial Growth Factor VEGFA upregulation for the treatment of peripheral artery disease. With our Platform Technology Co-Development Service Model, powered by unique in-house software, we're spearheading the search for regulatory small RNAs across a spectrum of diseases, from oncology to neuroinflammatory conditions. RNatives has state-of-the-art molecular biology laboratory in Kuopio, Finland. Our team is at the forefront of pioneering research to find the best modern RNA-medicine solutions.


website